We demonstrated that PD-L1 expression by either TPS or CPS, the line and agent of immunotherapeutic treatment, the histological melanoma subtype, and BRAF V600 mutation status were associated with response and/or overall survival after ICB treatment. Here, BRAF is linked to melanoma.